Facebook
Twitter
LinkedIn
ForwardTenecteplase for Acute Ischemic Stroke - Live
November 23, 2021
Intravenous thrombolytics is the mainstay of acute therapy in ischemic stroke. While alteplase has been FDA-approved for this indication since the 1990s, Tenecteplase has recently gained traction for usage in acute ischemic stroke treatment as well. This lecture summarizes the existing evidence and practical considerations for use of Tenecteplase in stroke therapy.
Target Audience
ED Physicians
Internal Medicine Physicians
Nurses
Stroke Coordinators
Learning Objectives
Learners will be able to:
- define the usage of tenecteplase for acute ischemic stroke
- assess the utility of tenecteplase as an alternative to alteplase in the correct clinical setting
- analyze some of the data from major tenecteplase trials
- demonstrate knowledge of proper tenecteplase administration techniques and protocols
Speaker(s)
Benzion Blech, M.D.
has no relevant financial relationships to disclose at this time.
Course Director(s)
Vahid Behravan, M.D.
has a financial relationship (Employment) with Johnson&Johnson;.
Peer Reviewer(s)
Vahid Behravan, M.D.
has a financial relationship (Employment) with Johnson&Johnson;.
Michelle Boudreau, D.O.
has no relevant financial relationships to disclose at this time.
We are working with a Joint Provider to provide CME accredited activities. Please allow up to 10 business days for your instructions on claiming your CME certificate.